The DOI matches its Crossref record; 159 of the 159 references it cites were found in a registry or an index.
Rapamycin passes the torch: a new generation of mTOR inhibitors
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
TOR signaling in growth and metabolism
Wullschleger, S., Loewith, R., & Hall, M. N. (2006) · Cell · doi:10.1016/j.cell.2006.01.016 · Cited by 5,787
Self-citationmTOR: from growth signal integration to cancer, diabetes and ageing
Zoncu, R., Efeyan, A., & Sabatini, D. M. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3025 · Cited by 3,941
TSC2 Mediates Cellular Energy Response to Control Cell Growth and Survival
Inoki, K., Zhu, T., & Guan, K.-L. (2003) · Cell · doi:10.1016/s0092-8674(03)00929-2 · Cited by 3,914
AMPK Phosphorylation of Raptor Mediates a Metabolic Checkpoint
Gwinn, D. M., Shackelford, D. B., Egan, D. F., Mihaylova, M. M., Mery, A., Vasquez, D. S., Turk, B. E., & Shaw, R. J. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.03.003 · Cited by 3,849
Rapamycin fed late in life extends lifespan in genetically heterogeneous mice
Harrison, D. E., Strong, R., Sharp, Z. D., Nelson, J. F., Astle, C. M., Flurkey, K., Nadon, N. L., Wilkinson, J. E., Frenkel, K., Carter, C. S., et al. (2009) · Nature · doi:10.1038/nature08221 · Cited by 3,766
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
Hudes, G., Carducci, M., Tomczak, P., Dutcher, J., Figlin, R., Kapoor, A., Staroslawska, E., Sosman, J., McDermott, D., Bodrogi, I., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066838 · Cited by 3,647
TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling
Inoki, K., Li, Y., Zhu, T., Wu, J., & Guan, K.-L. (2002) · Nature Cell Biology · doi:10.1038/ncb839 · Cited by 3,083
Motzer, R. J., Escudier, B., Oudard, S., Hutson, T. E., Porta, C., Bracarda, S., Grünwald, V., Thompson, J. A., Figlin, R. A., Hollaender, N., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61039-9 · Cited by 3,019
Kim, D.-H., Sarbassov, D. D., Ali, S. M., King, J. E., Latek, R. R., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2002) · Cell · doi:10.1016/s0092-8674(02)00808-5 · Cited by 2,986
Everolimus for Advanced Pancreatic Neuroendocrine Tumors
Yao, J. C., Shah, M. H., Ito, T., Bohas, C. L., Wolin, E. M., Van Cutsem, E., Hobday, T. J., Okusaka, T., Capdevila, J., de Vries, E. G. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009290 · Cited by 2,876
The Rag GTPases Bind Raptor and Mediate Amino Acid Signaling to mTORC1
Sancak, Y., Peterson, T. R., Shaul, Y. D., Lindquist, R. A., Thoreen, C. C., Bar-Peled, L., & Sabatini, D. M. (2008) · Science · doi:10.1126/science.1157535 · Cited by 2,773
Sarbassov, D. D., Ali, S. M., Kim, D.-H., Guertin, D. A., Latek, R. R., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2004) · Current Biology · doi:10.1016/j.cub.2004.06.054 · Cited by 2,665
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561
Sancak, Y., Bar-Peled, L., Zoncu, R., Markhard, A. L., Nada, S., & Sabatini, D. M. (2010) · Cell · doi:10.1016/j.cell.2010.02.024 · Cited by 2,464
Metformin and reduced risk of cancer in diabetic patients
Evans, J. M. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., & Morris, A. D. (2005) · BMJ · doi:10.1136/bmj.38415.708634.f7 · Cited by 2,388
Prolonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB
Sarbassov, D. D., Ali, S. M., Sengupta, S., Sheen, J.-H., Hsu, P. P., Bagley, A. F., Markhard, A. L., & Sabatini, D. M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.03.029 · Cited by 2,365
Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive
Jacinto, E., Loewith, R., Schmidt, A., Lin, S., Rüegg, M. A., Hall, A., & Hall, M. N. (2004) · Nature Cell Biology · doi:10.1038/ncb1183 · Cited by 2,114
Self-citationJung, C. H., Ro, S.-H., Cao, J., Otto, N. M., & Kim, D.-H. (2010) · FEBS Letters · doi:10.1016/j.febslet.2010.01.017 · Cited by 2,090
A mammalian protein targeted by G1-arresting rapamycin–receptor complex
Brown, E. J., Albers, M. W., Bum Shin, T., ichikawa, K., Keith, C. T., Lane, W. S., & Schreiber, S. L. (1994) · Nature · doi:10.1038/369756a0 · Cited by 2,053
Activation of a metabolic gene regulatory network downstream of mTOR complex 1
Düvel, K., Yecies, J. L., Menon, S., Raman, P., Lipovsky, A. I., Souza, A. L., Triantafellow, E., Ma, Q., Gorski, R., Cleaver, S., et al. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.06.022 · Cited by 2,020
Targets for Cell Cycle Arrest by the Immunosuppressant Rapamycin in Yeast
Heitman, J., Movva, N. R., & Hall, M. N. (1991) · Science · doi:10.1126/science.1715094 · Cited by 2,006
Self-citationABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
Tse, C., Shoemaker, A. R., Adickes, J., Anderson, M. G., Chen, J., Jin, S., Johnson, E. F., Marsh, K. C., Mitten, M. J., Nimmer, P., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5836 · Cited by 1,992
TOR, a Central Controller of Cell Growth
Schmelzle, T., & Hall, M. N. (2000) · Cell · doi:10.1016/s0092-8674(00)00117-3 · Cited by 1,924
Self-citationRheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling
Inoki, K., Li, Y., Xu, T., & Guan, K.-L. (2003) · Genes & Development · doi:10.1101/gad.1110003 · Cited by 1,911
Loewith, R., Jacinto, E., Wullschleger, S., Lorberg, A., Crespo, J. L., Bonenfant, D., Oppliger, W., Jenoe, P., & Hall, M. N. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00636-6 · Cited by 1,886
Self-citationRaptor, a Binding Partner of Target of Rapamycin (TOR), Mediates TOR Action
Hara, K., Maruki, Y., Long, X., Yoshino, K.-I., Oshiro, N., Hidayat, S., Tokunaga, C., Avruch, J., & Yonezawa, K. (2002) · Cell · doi:10.1016/s0092-8674(02)00833-4 · Cited by 1,810
Thoreen, C. C., Kang, S. A., Chang, J. W., Liu, Q., Zhang, J., Gao, Y., Reichling, L. J., Sim, T., Sabatini, D. M., & Gray, N. S. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m900301200 · Cited by 1,803
VÉZINA, C., KUDELSKI, A., & SEHGAL, S. N. (1975) · The Journal of Antibiotics · doi:10.7164/antibiotics.28.721 · Cited by 1,687
Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity
Um, S. H., Frigerio, F., Watanabe, M., Picard, F., Joaquin, M., Sticker, M., Fumagalli, S., Allegrini, P. R., Kozma, S. C., Auwerx, J., et al. (2004) · Nature · doi:10.1038/nature02866 · Cited by 1,677
Manning, B. D., Tee, A. R., Logsdon, M. N., Blenis, J., & Cantley, L. C. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00568-3 · Cited by 1,555
Sabatini, D. M., Erdjument-Bromage, H., Lui, M., Tempst, P., & Snyder, S. H. (1994) · Cell · doi:10.1016/0092-8674(94)90570-3 · Cited by 1,509
Hara, K., Yonezawa, K., Weng, Q.-P., Kozlowski, M. T., Belham, C., & Avruch, J. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.23.14484 · Cited by 1,367
Regulation of TORC1 by Rag GTPases in nutrient response
Kim, E., Goraksha-Hicks, P., Li, L., Neufeld, T. P., & Guan, K.-L. (2008) · Nature Cell Biology · doi:10.1038/ncb1753 · Cited by 1,349
Engelman, J. A., Chen, L., Tan, X., Crosby, K., Guimaraes, A. R., Upadhyay, R., Maira, M., McNamara, K., Perera, S. A., Song, Y., et al. (2008) · Nature Medicine · doi:10.1038/nm.1890 · Cited by 1,330
Tor, a Phosphatidylinositol Kinase Homologue, Controls Autophagy in Yeast
Noda, T., & Ohsumi, Y. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.7.3963 · Cited by 1,309
Regulation of lifespan in Drosophila by modulation of genes in the TOR signaling pathway
Kapahi, P., Zid, B. M., Harper, T., Koslover, D., Sapin, V., & Benzer, S. (2004) · Current Biology · doi:10.1016/j.cub.2004.03.059 · Cited by 1,293
Regulation of Yeast Replicative Life Span by TOR and Sch9 in Response to Nutrients
Kaeberlein, M., Powers, R. W., Steffen, K. K., Westman, E. A., Hu, D., Dang, N., Kerr, E. O., Kirkland, K. T., Fields, S., & Kennedy, B. K. (2005) · Science · doi:10.1126/science.1115535 · Cited by 1,293
Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or Lymphangioleiomyomatosis
Bissler, J. J., McCormack, F. X., Young, L. R., Elwing, J. M., Chuck, G., Leonard, J. M., Schmithorst, V. J., Laor, T., Brody, A. S., Bean, J., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa063564 · Cited by 1,253
A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin Signaling
Knight, Z. A., Gonzalez, B., Feldman, M. E., Zunder, E. R., Goldenberg, D. D., Williams, O., Loewith, R., Stokoe, D., Balla, A., Toth, B., et al. (2006) · Cell · doi:10.1016/j.cell.2006.03.035 · Cited by 1,174
RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1
Burnett, P. E., Barrow, R. K., Cohen, N. A., Snyder, S. H., & Sabatini, D. M. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.4.1432 · Cited by 1,138
The influence of glucose-lowering therapies on cancer risk in type 2 diabetes
Currie, C. J., Poole, C. D., & Gale, E. A. M. (2009) · Diabetologia · doi:10.1007/s00125-009-1440-6 · Cited by 1,124
The TSC1-2 tumor suppressor controls insulin–PI3K signaling via regulation of IRS proteins
Harrington, L. S., Findlay, G. M., Gray, A., Tolkacheva, T., Wigfield, S., Rebholz, H., Barnett, J., Leslie, N. R., Cheng, S., Shepherd, P. R., et al. (2004) · The Journal of Cell Biology · doi:10.1083/jcb.200403069 · Cited by 1,123
Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E
Fingar, D. C., Salama, S., Tsou, C., Harlow, E., & Blenis, J. (2002) · Genes & Development · doi:10.1101/gad.995802 · Cited by 1,093
Hsu, P. P., Kang, S. A., Rameseder, J., Zhang, Y., Ottina, K. A., Lim, D., Peterson, T. R., Choi, Y., Gray, N. S., Yaffe, M. B., et al. (2011) · Science · doi:10.1126/science.1199498 · Cited by 1,084
Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
Feldman, M. E., Apsel, B., Uotila, A., Loewith, R., Knight, Z. A., Ruggero, D., & Shokat, K. M. (2009) · PLoS Biology · doi:10.1371/journal.pbio.1000038 · Cited by 1,082
Tee, A. R., Manning, B. D., Roux, P. P., Cantley, L. C., & Blenis, J. (2003) · Current Biology · doi:10.1016/s0960-9822(03)00506-2 · Cited by 1,080
The LKB1 tumor suppressor negatively regulates mTOR signaling
Shaw, R. J., Bardeesy, N., Manning, B. D., Lopez, L., Kosmatka, M., DePinho, R. A., & Cantley, L. C. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.007 · Cited by 1,077
Influence of TOR kinase on lifespan in C. elegans
Vellai, T., Takacs-Vellai, K., Zhang, Y., Kovacs, A. L., Orosz, L., & Müller, F. (2003) · Nature · doi:10.1038/426620a · Cited by 1,057
Phosphatidic Acid-Mediated Mitogenic Activation of mTOR Signaling
Fang, Y., Vilella-Bach, M., Bachmann, R., Flanigan, A., & Chen, J. (2001) · Science · doi:10.1126/science.1066015 · Cited by 1,055
Insulin Activation of Rheb, a Mediator of mTOR/S6K/4E-BP Signaling, Is Inhibited by TSC1 and 2
Garami, A., Zwartkruis, F. J. T., Nobukuni, T., Joaquin, M., Roccio, M., Stocker, H., Kozma, S. C., Hafen, E., Bos, J. L., & Thomas, G. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00220-x · Cited by 1,043
New Users of Metformin Are at Low Risk of Incident Cancer
Libby, G., Donnelly, L. A., Donnan, P. T., Alessi, D. R., Morris, A. D., & Evans, J. M. M. (2009) · Diabetes Care · doi:10.2337/dc08-2175 · Cited by 996
Akt regulates growth by directly phosphorylating Tsc2
Potter, C. J., Pedraza, L. G., & Xu, T. (2002) · Nature Cell Biology · doi:10.1038/ncb840 · Cited by 959
Structure of the FKBP12-Rapamycin Complex Interacting with Binding Domain of Human FRAP
Choi, J., Chen, J., Schreiber, S. L., & Clardy, J. (1996) · Science · doi:10.1126/science.273.5272.239 · Cited by 929
Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins
Zhang, Y., Gao, X., Saucedo, L. J., Ru, B., Edgar, B. A., & Pan, D. (2003) · Nature Cell Biology · doi:10.1038/ncb999 · Cited by 923
García-Martínez, J. M., & Alessi, D. R. (2008) · Biochemical Journal · doi:10.1042/bj20081668 · Cited by 907
Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner
Kalender, A., Selvaraj, A., Kim, S. Y., Gulati, P., Brûlé, S., Viollet, B., Kemp, B. E., Bardeesy, N., Dennis, P., Schlager, J. J., et al. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2010.03.014 · Cited by 889
Isolation of a Protein Target of the FKBP12-Rapamycin Complex in Mammalian Cells
Sabers, C. J., Martin, M. M., Brunn, G. J., Williams, J. M., Dumont, F. J., Wiederrecht, G., & Abraham, R. T. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.2.815 · Cited by 887
Jiralerspong, S., Palla, S. L., Giordano, S. H., Meric-Bernstam, F., Liedtke, C., Barnett, C. M., Hsu, L., Hung, M.-C., Hortobagyi, G. N., & Gonzalez-Angulo, A. M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.19.6410 · Cited by 880
Yu, Y., Yoon, S.-O., Poulogiannis, G., Yang, Q., Ma, X. M., Villén, J., Kubica, N., Hoffman, G. R., Cantley, L. C., Gygi, S. P., et al. (2011) · Science · doi:10.1126/science.1199484 · Cited by 854
Phosphorylation of the Translational Repressor PHAS-I by the Mammalian Target of Rapamycin
Brunn, G. J., Hudson, C. C., Sekulić, A., Williams, J. M., Hosoi, H., Houghton, P. J., Lawrence, J. C., & Abraham, R. T. (1997) · Science · doi:10.1126/science.277.5322.99 · Cited by 846
Kunz, J., Henriquez, R., Schneider, U., Deuter-Reinhard, M., Movva, N. R., & Hall, M. N. (1993) · Cell · doi:10.1016/0092-8674(93)90144-f · Cited by 834
Self-citationChresta, C. M., Davies, B. R., Hickson, I., Harding, T., Cosulich, S., Critchlow, S. E., Vincent, J. P., Ellston, R., Jones, D., Sini, P., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1751 · Cited by 812
Choo, A. Y., Yoon, S.-O., Kim, S. G., Roux, P. P., & Blenis, J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809136105 · Cited by 810
Shah, O. J., Wang, Z., & Hunter, T. (2004) · Current Biology · doi:10.1016/j.cub.2004.08.026 · Cited by 798
mTORC1-Mediated Cell Proliferation, But Not Cell Growth, Controlled by the 4E-BPs
Dowling, R. J. O., Topisirovic, I., Alain, T., Bidinosti, M., Fonseca, B. D., Petroulakis, E., Wang, X., Larsson, O., Selvaraj, A., Liu, Y., et al. (2010) · Science · doi:10.1126/science.1187532 · Cited by 726
TOR controls translation initiation and early G1 progression in yeast.
Barbet, N. C., Schneider, U., Helliwell, S. B., Stansfield, I., Tuite, M. F., & Hall, M. N. (1996) · Molecular Biology of the Cell · doi:10.1091/mbc.7.1.25 · Cited by 715
Self-citationRapamycin blocks the phosphorylation of 4E-BP1 and inhibits cap-dependent initiation of translation.
Beretta, L., Gingras, A. C., Svitkin, Y. V., Hall, M. N., & Sonenberg, N. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00398.x · Cited by 677
Self-citationTsc tumour suppressor proteins antagonize amino-acid–TOR signalling
Gao, X., Zhang, Y., Arrazola, P., Hino, O., Kobayashi, T., Yeung, R. S., Ru, B., & Pan, D. (2002) · Nature Cell Biology · doi:10.1038/ncb847 · Cited by 672
Kwiatkowski, D. J. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.5.525 · Cited by 667
Activation of mTORC2 by Association with the Ribosome
Zinzalla, V., Stracka, D., Oppliger, W., & Hall, M. N. (2011) · Cell · doi:10.1016/j.cell.2011.02.014 · Cited by 654
Self-citationmTORC1 controls fasting-induced ketogenesis and its modulation by ageing
Sengupta, S., Peterson, T. R., Laplante, M., Oh, S., & Sabatini, D. M. (2010) · Nature · doi:10.1038/nature09584 · Cited by 646
Hess, G., Herbrecht, R., Romaguera, J., Verhoef, G., Crump, M., Gisselbrecht, C., Laurell, A., Offner, F., Strahs, A., Berkenblit, A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.7977 · Cited by 641
Bentzinger, C. F., Romanino, K., Cloëtta, D., Lin, S., Mascarenhas, J. B., Oliveri, F., Xia, J., Casanova, E., Costa, C. F., Brink, M., et al. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.10.002 · Cited by 640
Self-citationmTOR Is Essential for Growth and Proliferation in Early Mouse Embryos and Embryonic Stem Cells
Murakami, M., Ichisaka, T., Maeda, M., Oshiro, N., Hara, K., Edenhofer, F., Kiyama, H., Yonezawa, K., & Yamanaka, S. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.15.6710-6718.2004 · Cited by 624
Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling
Ikenoue, T., Inoki, K., Yang, Q., Zhou, X., & Guan, K. (2008) · The EMBO Journal · doi:10.1038/emboj.2008.119 · Cited by 610
A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma
Fan, Q.-W., Knight, Z. A., Goldenberg, D. D., Yu, W., Mostov, K. E., Stokoe, D., Shokat, K. M., & Weiss, W. A. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.03.029 · Cited by 585
Antidiabetic Therapies Affect Risk of Pancreatic Cancer
Li, D., Yeung, S. J., Hassan, M. M., Konopleva, M., & Abbruzzese, J. L. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.04.013 · Cited by 584
Role of mTOR in podocyte function and diabetic nephropathy in humans and mice
Gödel, M., Hartleben, B., Herbach, N., Liu, S., Zschiedrich, S., Lu, S., Debreczeni-Mór, A., Lindenmeyer, M. T., Rastaldi, M.-P., Hartleben, G., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44774 · Cited by 547
Self-citationRegulation of eIF-4E BP1 Phosphorylation by mTOR
Hara, K., Yonezawa, K., Kozlowski, M. T., Sugimoto, T., Andrabi, K., Weng, Q.-P., Kasuga, M., Nishimoto, I., & Avruch, J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.42.26457 · Cited by 527
Gangloff, Y.-G., Mueller, M., Dann, S. G., Svoboda, P., Sticker, M., Spetz, J.-F., Um, S. H., Brown, E. J., Cereghini, S., Thomas, G., et al. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.21.9508-9516.2004 · Cited by 485
RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12/rapamycin complex.
Chiu, M. I., Katz, H., & Berlin, V (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.26.12574 · Cited by 481
Adipose-Specific Knockout of raptor Results in Lean Mice with Enhanced Mitochondrial Respiration
Polak, P., Cybulski, N., Feige, J. N., Auwerx, J., Rüegg, M. A., & Hall, M. N. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.09.003 · Cited by 480
Self-citationTabernero, J., Rojo, F., Calvo, E., Burris, H., Judson, I., Hazell, K., Martinelli, E., Cajal, S. R. Y., Jones, S., Vidal, L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.5482 · Cited by 474
Inhibition of the immune response by rapamycin, a new antifungal antibiotic
Martel, R. R., Klicius, J., & Galet, S. (1977) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y77-007 · Cited by 463
Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR)
García-Martínez, J. M., Moran, J., Clarke, R. G., Gray, A., Cosulich, S. C., Chresta, C. M., & Alessi, D. R. (2009) · Biochemical Journal · doi:10.1042/bj20090489 · Cited by 455
Rapamycin and mTOR kinase inhibitors
Ballou, L. M., & Lin, R. Z. (2008) · Journal of Chemical Biology · doi:10.1007/s12154-008-0003-5 · Cited by 442
Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases
Apsel, B., Blair, J. A., Gonzalez, B., Nazif, T. M., Feldman, M. E., Aizenstein, B., Hoffman, R., Williams, R. L., Shokat, K. M., & Knight, Z. A. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.117 · Cited by 440
Hsieh, A. C., Costa, M., Zollo, O., Davis, C., Feldman, M. E., Testa, J. R., Meyuhas, O., Shokat, K. M., & Ruggero, D. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.01.021 · Cited by 434
Muscle inactivation of mTOR causes metabolic and dystrophin defects leading to severe myopathy
Risson, V., Mazelin, L., Roceri, M., Sanchez, H., Moncollin, V., Corneloup, C., Richard-Bulteau, H., Vignaud, A., Baas, D., Defour, A., et al. (2009) · Journal of Cell Biology · doi:10.1083/jcb.200903131 · Cited by 381
Castro, A. F., Rebhun, J. F., Clark, G. J., & Quilliam, L. A. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.c300226200 · Cited by 381
Structure of the Human mTOR Complex I and Its Implications for Rapamycin Inhibition
Yip, C. K., Murata, K., Walz, T., Sabatini, D. M., & Kang, S. A. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.05.017 · Cited by 372
mTOR Complex 2 Is Required for the Development of Prostate Cancer Induced by Pten Loss in Mice
Guertin, D. A., Stevens, D. M., Saitoh, M., Kinkel, S., Crosby, K., Sheen, J.-H., Mullholland, D. J., Magnuson, M. A., Wu, H., & Sabatini, D. M. (2009) · Cancer Cell · doi:10.1016/j.ccr.2008.12.017 · Cited by 355
Cao, K., Graziotto, J. J., Blair, C. D., Mazzulli, J. R., Erdos, M. R., Krainc, D., & Collins, F. S. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002346 · Cited by 350
Amino acid availability regulates p70 S6 kinase and multiple translation factors
WANG, X., CAMPBELL, L. E., MILLER, C. M., & PROUD, C. G. (1998) · Biochemical Journal · doi:10.1042/bj3340261 · Cited by 338
Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor
Janes, M. R., Limon, J. J., So, L., Chen, J., Lim, R. J., Chavez, M. A., Vu, C., Lilly, M. B., Mallya, S., Ong, S. T., et al. (2010) · Nature Medicine · doi:10.1038/nm.2091 · Cited by 337
Huber, A., Bodenmiller, B., Uotila, A., Stahl, M., Wanka, S., Gerrits, B., Aebersold, R., & Loewith, R. (2009) · Genes & Development · doi:10.1101/gad.532109 · Cited by 334
Oh, W. J., Wu, C. ‐., Kim, S. J., Facchinetti, V., Julien, L. ‐., Finlan, M., Roux, P. P., Su, B., & Jacinto, E. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.271 · Cited by 333
Yu, K., Toral-Barza, L., Shi, C., Zhang, W.-G., Lucas, J., Shor, B., Kim, J., Verheijen, J., Curran, K., Malwitz, D. J., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0299 · Cited by 330
Garlich, J. R., De, P., Dey, N., Su, J. D., Peng, X., Miller, A., Murali, R., Lu, Y., Mills, G. B., Kundra, V., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-0669 · Cited by 279
Wright, J. L., & Stanford, J. L. (2009) · Cancer Causes & Control · doi:10.1007/s10552-009-9407-y · Cited by 276
Raynaud, F. I., Eccles, S. A., Patel, S., Alix, S., Box, G., Chuckowree, I., Folkes, A., Gowan, S., De Haven Brandon, A., Di Stefano, F., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-1200 · Cited by 271
Role of mTOR Signaling in Tumor Cell Motility, Invasion and Metastasis
Huang, S., & Zhou, H. (2011) · Current Protein & Peptide Science · doi:10.2174/138920311795659407 · Cited by 270
TOR2 is required for organization of the actin cytoskeleton in yeast
Schmidt, A., Kunz, J., & Hall, M. N. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.24.13780 · Cited by 262
Self-citationSoulard, A., Cremonesi, A., Moes, S., Schütz, F., Jenö, P., & Hall, M. N. (2010) · Molecular Biology of the Cell · doi:10.1091/mbc.e10-03-0182 · Cited by 262
Self-citationShende, P., Plaisance, I., Morandi, C., Pellieux, C., Berthonneche, C., Zorzato, F., Krishnan, J., Lerch, R., Hall, M. N., Rüegg, M. A., et al. (2011) · Circulation · doi:10.1161/circulationaha.110.977066 · Cited by 239
Self-citationMolecular Organization of Target of Rapamycin Complex 2
Wullschleger, S., Loewith, R., Oppliger, W., & Hall, M. N. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m505553200 · Cited by 234
Self-citationLiu, Q., Wang, J., Kang, S. A., Thoreen, C. C., Hur, W., Ahmed, T., Sabatini, D. M., & Gray, N. S. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm101520v · Cited by 219
Yu, K., Shi, C., Toral-Barza, L., Lucas, J., Shor, B., Kim, J. E., Zhang, W.-G., Mahoney, R., Gaydos, C., Tardio, L., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2340 · Cited by 206
Mediobasal Hypothalamic p70 S6 Kinase 1 Modulates the Control of Energy Homeostasis
Blouet, C., Ono, H., & Schwartz, G. J. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.10.004 · Cited by 198
Comparison of acute rapamycin nephrotoxicity with cyclosporine and FK506
Andoh, T. F., Burdmann, E. A., Fransechini, N., Houghton, D. C., & Bennett, W. M. (1996) · Kidney International · doi:10.1038/ki.1996.417 · Cited by 186
Targeting Eukaryotic Translation Initiation Factor 4E (eIF4E) in Cancer
Hsieh, A. C., & Ruggero, D. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0433 · Cited by 186
Temsirolimus, an Inhibitor of Mammalian Target of Rapamycin
Rini, B. I. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4719 · Cited by 183
Carayol, N., Vakana, E., Sassano, A., Kaur, S., Goussetis, D. J., Glaser, H., Druker, B. J., Donato, N. J., Altman, J. K., Barr, S., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1005114107 · Cited by 180
mTOR complex 2 in adipose tissue negatively controls whole-body growth
Cybulski, N., Polak, P., Auwerx, J., Rüegg, M. A., & Hall, M. N. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811321106 · Cited by 174
Self-citationTargeting the mTOR kinase domain: the second generation of mTOR inhibitors
Zhang, Y.-J., Duan, Y., & Zheng, X. F. S. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.02.008 · Cited by 173
Cirstea, D., Hideshima, T., Rodig, S., Santo, L., Pozzi, S., Vallet, S., Ikeda, H., Perrone, G., Gorgun, G., Patel, K., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0763 · Cited by 167
Veverka, V., Crabbe, T., Bird, I., Lennie, G., Muskett, F. W., Taylor, R. J., & Carr, M. D. (2007) · Oncogene · doi:10.1038/sj.onc.1210693 · Cited by 163
Human brain tumor xenografts in nude mice as a chemotherapy model
Houchens, D. P., Ovejera, A. A., Riblet, S. M., & Slagel, D. E. (1983) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(83)90012-3 · Cited by 163
Rictor/mTORC2 Is Essential for Maintaining a Balance Between β-Cell Proliferation and Cell Size
Gu, Y., Lindner, J., Kumar, A., Yuan, W., & Magnuson, M. A. (2011) · Diabetes · doi:10.2337/db10-1194 · Cited by 161
Molckovsky, A., & Siu, L. L. (2008) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-1-20 · Cited by 159
Recent Advances in the Therapeutic Perspectives of Nutlin-3
Secchiero, P., Bosco, R., Celeghini, C., & Zauli, G. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211795222586 · Cited by 158
Mammalian Target of Rapamycin: Hitting the Bull′s‐Eye for Neurological Disorders
Chong, Z. Z., Shang, Y., Zhang, L., Wang, S., & Maiese, K. (2010) · Oxidative Medicine and Cellular Longevity · doi:10.4161/oxim.3.6.14787 · Cited by 149
NVP-BEZ235 as a New Therapeutic Option for Sarcomas
Manara, M. C., Nicoletti, G., Zambelli, D., Ventura, S., Guerzoni, C., Landuzzi, L., Lollini, P., Maira, S.-M., Garcı́a-Echeverrı́a, C., Mercuri, M., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0816 · Cited by 149
Refined structure of the FKBP12–rapamycin–FRB ternary complex at 2.2 Å resolution
Liang, J., Choi, J., & Clardy, J. (1999) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444998014747 · Cited by 148
Dames, S. A., Mulet, J. M., Rathgeb–Szabo, K., Hall, M. N., & Grzesiek, S. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501116200 · Cited by 134
Self-citationRegulation of Elongation Phase of mRNA Translation in Diabetic Nephropathy
Sataranatarajan, K., Mariappan, M. M., Lee, M. J., Féliers, D., Choudhury, G. G., Barnes, J. L., & Kasinath, B. S. (2007) · American Journal Of Pathology · doi:10.2353/ajpath.2007.070412 · Cited by 121
Baumann, P., Mandl–Weber, S., Oduncu, F. S., & Schmidmaier, R. (2008) · Experimental Cell Research · doi:10.1016/j.yexcr.2008.11.007 · Cited by 121
Targeting Melanoma with Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitors
Marone, R., Erhart, D., Mertz, A. C., Bohnacker, T., Schnell, C., Cmiljanović, V., Stauffer, F., García-Echeverría, C., Giese, B., Maira, S.-M., et al. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0366 · Cited by 119
Gabardi, S., & Baroletti, S. A. (2010) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.30.10.1044 · Cited by 119
Bunpo, P., Dudley, A., Cundiff, J. K., Cavener, D. R., Wek, R. C., & Anthony, T. G. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.047910 · Cited by 116
Ikezoe, T., Nishioka, C., Bandobashi, K., Yang, Y., Kuwayama, Y., Adachi, Y., Takeuchi, T., Koeffler, H. P., & Taguchi, H. (2006) · Leukemia Research · doi:10.1016/j.leukres.2006.08.001 · Cited by 116
Xue, Q., Hopkins, B. D., Perruzzi, C. A., Udayakumar, D., Sherris, D., & Benjamin, L. E. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-2058 · Cited by 112
Deforolimus (AP23573) a novel mTOR inhibitor in clinical development
Mita, M. M., Sankhala, K. K., Abdel-Karim, I., Mita, A. C., & Giles, F. J. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780802556485 · Cited by 109
Falcón, B. L., Barr, S. M., Gokhale, P. C., Chou, J., Fogarty, J., Depeille, P., Miglarese, M. R., Epstein, D. M., & McDonald, D. M. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3126 · Cited by 95
Rao, R. D., Mladek, A. C., Lamont, J. D., Goble, J. M., Erlichman, C., James, C. D., & Sarkaria, J. N. (2005) · Neoplasia · doi:10.1593/neo.05361 · Cited by 95
Sini, P., James, D. I., Chresta, C. M., & Guichard, S. M. (2010) · Autophagy · doi:10.4161/auto.6.4.11671 · Cited by 90
Drosophila Target of Rapamycin Kinase Functions as a Multimer
Zhang, Y., Billington, C. J., Pan, D., & Neufeld, T. P. (2005) · Genetics · doi:10.1534/genetics.105.051979 · Cited by 83
Vertical Targeting of the Phosphatidylinositol-3 Kinase Pathway as a Strategy for Treating Melanoma
Aziz, S. A., Jilaveanu, L. B., Zito, C. R., Camp, R. L., Rimm, D. L., Conrad, P. J., & Kluger, H. M. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1490 · Cited by 80
Differential Requirement of mTOR in Postmitotic Tissues and Tumorigenesis
Nardella, C., Carracedo, A., Alimonti, A., Hobbs, R. M., Clohessy, J. G., Chen, Z., Egia, A., Fornari, A., Fiorentino, M., Loda, M. F., et al. (2009) · Science Signaling · doi:10.1126/scisignal.2000189 · Cited by 77
Mallon, R. G., Hollander, I. J., Feldberg, L. R., Lucas, J., Soloveva, V., Venkatesan, A. M., Dehnhardt, C. M., Santos, E. D., Chen, Z., dos Santos, O., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0954 · Cited by 65
Targeting the Akt/mTOR pathway in Brca1-deficient cancers
Xiang, T., Jia, Y., Sherris, D., Li, S., Wang, H., Lu, D., & Yang, Q. (2011) · Oncogene · doi:10.1038/onc.2010.603 · Cited by 53
McMahon, L. P., Yue, W., Santen, R. J., & Lawrence, J. C. (2004) · Molecular Endocrinology · doi:10.1210/me.2004-0305 · Cited by 53
The FRB Domain of mTOR: NMR Solution Structure and Inhibitor Design ,
Leone, M., Crowell, K. J., Chen, J., Jung, D., Chiang, G. G., Sareth, S., Abraham, R. T., & Pellecchia, M. (2006) · Biochemistry · doi:10.1021/bi060976+ · Cited by 51
Tan, D. S.-W., Dumez, H., Olmos, D., Sandhu, S. K., Hoeben, A., Stephens, A. W., Poondru, S., Gedrich, R. W., Kaye, S. B., & Schöffski, P. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.3006 · Cited by 50
Genome-wide shRNA screen reveals increased mitochondrial dependence upon mTORC2 addiction
Colombi, M., Molle, K. D., Benjamin, D., Rattenbacher-Kiser, K. F., Schaefer, C., Betz, C., Thiemeyer, A., Regenass, U., Hall, M. N., & Moroni, C. (2010) · Oncogene · doi:10.1038/onc.2010.539 · Cited by 48
Self-citationChong, C. R., & Chabner, B. A. (2009) · The Oncologist · doi:10.1634/theoncologist.2009-0286 · Cited by 47
Ayral‐Kaloustian, S., Gu, J., Lucas, J., Cinque, M., Gaydos, C., Zask, A., Chaudhary, I., Wang, J., Di, L., Young, M., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm901427g · Cited by 46
Insights into the domain and repeat architecture of target of rapamycin
Knutson, B. A. (2010) · Journal of Structural Biology · doi:10.1016/j.jsb.2010.01.002 · Cited by 41
Gravina, G. L., Marampon, F., Petini, F., Biordi, L. A., Sherris, D., Jannini, E. A., Tombolini, V., & Festuccia, C. (2011) · Endocrine Related Cancer · doi:10.1530/erc-11-0045 · Cited by 40
Benefits of mTOR kinase targeting in oncology: pre-clinical evidence with AZD8055
Marshall, G. B., Howard, Z., Dry, J. R., Fenton, S. E., Heathcote, D., Gray, N. M., Keen, H. G., Logié, A., Holt, S. V., Smith, P. D., et al. (2011) · Biochemical Society Transactions · doi:10.1042/bst0390456 · Cited by 40
Lewis, G. P., Chapin, E. A., Byun, J., Luna, G., Sherris, D., & Fisher, S. K. (2009) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.09-3445 · Cited by 37
Li, T., Wang, J., Wang, X., Yang, N. Y., Chen, S.-M., Tong, L., Yang, C., Meng, L., & Ding, J. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.167940 · Cited by 37
Activating Mutations in TOR Are in Similar Structures As Oncogenic Mutations in PI3KCα
Sturgill, T. W., & Hall, M. N. (2009) · ACS Chemical Biology · doi:10.1021/cb900193e · Cited by 35
Self-citationJaafar, R., Zeiller, C., Pirola, L., Grazia, A. D., Naro, F., Vidal, H., Lefai, É., & Némoz, G. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.203885 · Cited by 33
Rapamycin-mediated FOXO1 inactivation reduces the anticancer efficacy of rapamycin.
Abdelnour‐Berchtold, E., Cerantola, Y., Roulin, D., Dormond-Meuwly, A., Demartines, N., & Dormond, O. (2010) · PubMed · Cited by 33
Recent advances in the discovery of small-molecule ATP competitive mTOR inhibitors: a patent review
Zask, A., Verheijen, J. C., & Richard, D. J. (2011) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2011.584871 · Cited by 30
Baumann, P., Hagemeier, H., Mandl–Weber, S., Franke, D., & Schmidmaier, R. (2009) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e328328d18b · Cited by 29
Abstract B148: INK128 is a potent and selective TORC1/2 inhibitor with broad oral antitumor activity
Jessen, K. A., Wang, S., Kessler, L. V., Guo, X., Kucharski, J. M., Staunton, J., Lan, L., Elia, M., Stewart, J., Brown, J., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.targ-09-b148 · Cited by 25
Cited by
MTOR: a pharmacologic target for autophagy regulation
Kim, Y. C., & Guan, K.-L. (2015) · Journal of Clinical Investigation · doi:10.1172/jci73939 · Cited by 2,126
mTOR is a key modulator of ageing and age-related disease
Johnson, S. C., Rabinovitch, P. S., & Kaeberlein, M. (2013) · Nature · doi:10.1038/nature11861 · Cited by 1,676
Rapamycin: one drug, many effects
Li, J., Kim, S. G., & Blenis, J. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.01.001 · Cited by 1,287
mTOR signalling and cellular metabolism are mutual determinants in cancer
Mossmann, D., Park, S., & Hall, M. N. (2018) · Nature reviews. Cancer · doi:10.1038/s41568-018-0074-8 · Cited by 1,088
Self-citationMaking new contacts: the mTOR network in metabolism and signalling crosstalk
Shimobayashi, M., & Hall, M. N. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3757 · Cited by 1,053
Metadata
- Authors
- Benjamin, D., Colombi, M., Moroni, C., & Hall, M. N.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2011-10-31
- Volume
- 10
- Issue
- 11
- Pages
- 868-880
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2029348880
- Cited by
- 989
- References
- 159
- FWCI
- 5.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.